Clinical Trials Directory

Trials / Completed

CompletedNCT06094582

Knowledges and Use of Cannabidiol in Older Adults

Knowledges and Use of Cannabidiol in Older Adults Aged 65 Years and Over in France

Status
Completed
Phase
Study type
Observational
Enrollment
47 (actual)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
65 Years – 120 Years
Healthy volunteers
Accepted

Summary

The use of non-medical cannabidiol (CBD) has been growing recently in France and in the world, in young but also older adults. Few data are available on the use of cannabidiol in older adults. A better knowledge of the use of cannabidiol in older adults, and of their own knowledges of the molecule, is necessary to guide and follow the CBD uptake in this population and avoid potential adverse events.

Detailed description

Cannabidiol may be used by patients because it may have beneficial pharmacological effects (including anxiolytic, analgesic, anti-inflammatories or antioxidant effects). Older adults aged 65 years and over, are more frequently at risk of multimorbidity and loss of autonomy, and may present with several symptoms like pain, anxiety, sleep disturbances, that may potentially respond to CBD. The molecule is often marketed as devoid of adverse effects. Nevertheless, with ageing, reduction in liver and kidney function, may have an impact on the metabolism and elimination of CBD and increase the risk of side-effect. As well, the risk of interaction with drugs frequently prescribed in older adults such as CYP3A4 inhibitors (verapamil, ketoconazole …), CYP3A4 inducers (phenytoin, carbamazepine, …) or CY92C19 inhibitors or inducers (fluoxetine …), may increase the risk of side effects. Our hypothesis is that the use of CBD has increased last years in older adults, but that they are insufficiently informed about this molecule. There is a need to assess the prevalence of CBD use in older adults in France, to assess the knowledges of CBD users about this substance, and to better characterize CBD users.

Conditions

Interventions

TypeNameDescription
OTHERquestionnaireParticipants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.

Timeline

Start date
2023-10-26
Primary completion
2023-12-26
Completion
2023-12-26
First posted
2023-10-23
Last updated
2025-12-22

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06094582. Inclusion in this directory is not an endorsement.